Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Ivermectin and COVID-19 in Care Home: Case Report

Loue et al., J. Infectious Diseases and Epidemiology, doi:10.23937/2474-3658/1510202
Apr 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 70% Improvement Relative Risk Severe case 55% Ivermectin for COVID-19  Loue et al.  EARLY TREATMENT Is early treatment with ivermectin beneficial for COVID-19? Retrospective 25 patients in France Lower mortality (p=0.34) and severe cases (p=0.11), not sig. Loue et al., J. Infectious Diseases an.., Apr 2021 Favorsivermectin Favorscontrol 0 0.5 1 1.5 2+
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments.
Small quasi-randomized (patient choice) study with 25 PCR+ patients in a nursing home offered ivermectin, of which 10 chose to be treated. The mean age was 83.5 in the treatment group and 81.8 in the control group. There was lower mortality and fewer serious cases with treatment.
This is the 50th of 104 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
51 studies are RCTs, which show efficacy with p=0.00000015.
risk of death, 70.0% lower, RR 0.30, p = 0.34, treatment 1 of 10 (10.0%), control 5 of 15 (33.3%), NNT 4.3.
risk of severe case, 55.0% lower, RR 0.45, p = 0.11, treatment 3 of 10 (30.0%), control 10 of 15 (66.7%), NNT 2.7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Loue et al., 17 Apr 2021, retrospective quasi-randomized (patient choice), France, peer-reviewed, 2 authors, dosage 200μg/kg single dose.
This PaperIvermectinAll
Ivermectin and COVID-19 in Care Home: Case Report
Loué Pierre, Fardeau Christine
Journal of Infectious Diseases and Epidemiology, doi:10.23937/2474-3658/1510202
Check for updates droxychloroquine and azithromycin. Ivermectin (IVM) was suggested empirically as known for in vivo anti dengue Flavivirus [5] and in vitro antiviral activity against HIV [6] dengue [7, 8] and chikungunya [8] . In care home IVM is an option for treatment of scabies, including for community infection control [9] . In the other hand IVM is worldwide used for the treatment of river blindness caused by onchocerciasis infection [10] . Side effects including mainly allergic rash and decrease in tension, were declared at a very low rate [9, 10] . Of the 25 PCR-positive patients, 10 chose to take the IVM treatment (group 1) and 15 chose not to take IVM (group 2). Patients of the group 1 received a single dose of 200 micrograms/kg body weight. Individual daily medical check was scheduled for the 2 months of the lockdown period that lasted from April 3 to May 15, 2020 for all patients. The monitoring protocol, imple-
Bernigaud, Guillemot, Ahmed-Belkacem, Grimaldi-Bensouda, Lespine, Oral ivermectin for a scabies outbreak in a long-term-care facility: Potential value in preventing COVID-19 and associated mortality, Br J Dermatol
Boussinesq, Chipaux, Ernould, Prod'hon, Quillévéré, Efficacité parasitologique de traite
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Chaccour, Ruiz-Castillo, Richardson, Moncunill, Casellas, The SARS-CoV-2 ivermectin navarra-isglobal trial (SAINT) to evaluate the potential of ivermectin to reduce COVID-19 transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial, Trials
Changeux, Amoura, Rey, Miyara, A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications, C R Biol
Changeux, The nicotinic acetylcholine receptor: A typical 'allosteric machine, Philos Trans R Soc Lond B Biol Sci
Guerrero, Bravo, Muñoz, Grillo, Guerrero, COVID-19: The ivermectin African enigma, Colomb Med
Insee, Évolution du nombre de décès entre le premier mars et le 30 avril
Lespine, Alvinerie, Sutra, Pors, Chartier, Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat, Vet Parasitol
Momekov, Momekova, Ivermectin as a potential Covid-19 treatment from the pharmacokinetic point of view: Antiviral levels are not likely attainable with known dosing regimens, MedRxiv, doi:10.1101/2020.04.11.20061804v2
Romani, Marks, Sokana, Nasi, Kamoriki, Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: A single-arm community intervention trial, Lancet Infect Dis
Santos, Natural history of COVID-19 and current knowledge on treatment therapeutic options, Biomed Pharmacother
Susen, Tacquard, Godon, Mansour, Garrigue, Traitements anticoagulant pour la prévention du risque thrombotique chez un patient hospitalisé avec covid-19 et surveillance de l'hémostase
Tay, Fraser, Chan, Moreland, Rathore, Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antivir Res
Varghese, Kaukinen, Glaesker, Bespalov, Hanski, Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses, Antivir Res
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J
Yamasmith, Saleh-Arong Fa-H, Avirutnan, Angkasekwinai, Mairiang, Efficacy and safety of ivermectin against dengue infection: A phase III, randomized, double-blind, placebo-controlled trial
Yan, Ci, Chen, Chen, Li, Anti-inflammatory effect of ivermectin in mouse model of allergic asthma, Inflamm Res
Yang, Atkinson, Wang, Lee, Bogoyevitch, The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antiviral Res
{ 'indexed': {'date-parts': [[2022, 3, 29]], 'date-time': '2022-03-29T23:35:42Z', 'timestamp': 1648596942379}, 'reference-count': 0, 'publisher': 'ClinMed International Library', 'issue': '4', 'content-domain': {'domain': [''], 'crossmark-restriction': True}, 'DOI': '10.23937/2474-3658/1510202', 'type': 'journal-article', 'created': {'date-parts': [[2021, 4, 22]], 'date-time': '2021-04-22T12:42:39Z', 'timestamp': 1619095359000}, 'update-policy': '', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Ivermectin and COVID-19 in Care Home: Case Report', 'prefix': '10.23937', 'volume': '7', 'author': [ {'given': 'Loué', 'family': 'Pierre', 'sequence': 'first', 'affiliation': []}, {'given': 'Fardeau', 'family': 'Christine', 'sequence': 'additional', 'affiliation': []}], 'member': '10022', 'published-online': {'date-parts': [[2021, 4, 30]]}, 'container-title': 'Journal of Infectious Diseases and Epidemiology', 'original-title': [], 'deposited': { 'date-parts': [[2021, 4, 22]], 'date-time': '2021-04-22T12:42:41Z', 'timestamp': 1619095361000}, 'score': 1, 'resource': { 'primary': { 'URL': ''}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 4, 30]]}, 'references-count': 0, 'journal-issue': {'issue': '4', 'published-online': {'date-parts': [[2021, 4, 30]]}}, 'URL': '', 'relation': {}, 'ISSN': ['2474-3658'], 'subject': ['General Medicine'], 'container-title-short': 'J Infect Dis Epidemiol', 'published': {'date-parts': [[2021, 4, 30]]}}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop